DECEMBER 5-9, 2023



Call for Abstracts 2023

Call for Abstracts

2023 San Antonio Breast Cancer Symposium Call for Abstracts is now open.

Presenters of accepted abstracts for oral presentations, spotlight poster presentations and poster presentations are required to participate onsite. 


  • Abstract must be submitted online.
  • The abstract must be in English.
  • There is no limit to the number of abstracts submitted.
  • The size limit for the abstract (including title, body and tables) is 3400 characters. This does not include spaces.
  • Please see the submissions website for specific details regarding the inclusion of tables. Tables count for 320 characters.
  • Figures cannot be included in an abstract.
  • Any author who cannot present on a particular day of the week must provide that information by emailing
  • Submitting an abstract online does not register you to attend the Symposium. 
  • Presenters of accepted abstracts for oral presentations, spotlight poster presentations and poster presentations are required to participate onsite. 

Submission Fee

  • Include a payment of $50.00 for each regular abstract submitted. The submission fee for late-breaking abstracts is $100.00.
  • A credit card payment is required.
  • The abstract fee is not refundable.
  • Abstracts will be due July 10, 2023.  
  • The deadline for late breaking abstracts will be September 30, 2023

Submission Deadlines

  • Abstracts must be submitted online the submission portal.
  • When finished with your online submission, be sure to submit payment. Click the "Submit" button.  Abstracts received without a properly completed Financial Disclosure Declaration will not be considered.  The size limit for the abstract (including title, body, and tables) is 3400 characters - this does not include spaces. Please see the submissions website for specific details regarding tables.
  • July 10, 2023: Abstract Submission Deadline (11:59:00 PM CT)
  • July 17, 2023: Abstract Minor Correction Deadline (no changes/corrections will be permitted after July 17)
  • Late September/Early October 2023: Decision Letters and Presentation Instructions Emailed to Presenters (contact person/first author listed)
  • August 21, 2023: Late Breaking Abstract Submission Opens
  • September 30, 2023: Late Breaking Abstract Submission Deadline (11:59:00 PM CT)

Abstract Subject Categories

The subject categories for abstract submission are listed below. You must select the most appropriate category for your abstract and insert its corresponding number in the box on the abstract form. Please be aware that the Symposium Abstract Review Committee may re-categorize your abstract if doing so is deemed appropriate.

Subject Categories List

  • Adverse Effects of Cancer Treatment and Symptom Management
  • Animal and ex vivo Models
  • Artificial Intelligence, Computational Biology, and Systems Biology
  • Behavioral and Population Science
  • Breast Cancer Risk, Genetics, and Prevention
  • Breast Cancer: Early Stage - HER2+
  • Breast Cancer: Early Stage - Hormone Receptor Positive
  • Breast Cancer: Early Stage - Other
  • Breast Cancer: Early Stage - Triple Negative
  • Breast Cancer: Metastatic - HER2+
  • Breast Cancer: Metastatic - Hormone Receptor Positive
  • Breast Cancer: Metastatic - Other
  • Breast Cancer: Metastatic - Triple Negative
  • Cancer Health Disparities
  • Cancer Survivorship and Quality of Life
  • Clinical Biomarkers, Translational Research, and Precision Medicine
  • Clinical Case Studies
  • Drug Discovery, Design, and Delivery
  • Experimental Therapeutics and Early Phase Trials
  • Imaging / Early Detection
  • Mechanisms of Resistance
  • Molecular and Cell Tumor Biology
  • Ongoing Clinical Trials (see rules below)
  • Pathology
  • Policy, Access to Care, Health Outcomes and Cancer Care Delivery
  • Radiation Oncology
  • Real-World Data and Real-World Evidence
  • Surgery
  • Tumor Microenvironment, Immunology, and Angiogenesis
  • Other


This category is for work that is ongoing. It is to inform and inspire, and/or to invite the collaboration of others. It is to not to discuss the trial results, either preliminary or formally completed - presentations with this type of information should be submitted as regular abstracts. 

Trials with any type of focus may be submitted (treatment, prevention, biomarker endpoints, supportive care, educational, and psychosocial endpoints). 

What should be presented in the abstract and eventually in the poster is: 

  • A brief background discussion
  • Trial design
  • Eligibility criteria
  • Specific aims
  • Statistical methods
  • Present accrual and target accrual
  • Contact information for people with a specific interest in the trial

Again, inclusion of preliminary or final trial results will disqualify an abstract in this category and is not allowed on the poster, though information on accrual to date or confirmation of feasibility is acceptable. Poster presentations in the Ongoing Clinical Trials category are not subject to SABCS pre-publication and embargo policies.

Clinical Case Studies

This category is for clinical cases or clinical vignettes to present interesting patient cases. Only submissions with a clinical trainee as the corresponding author will be considered for presentation (example - medical student, resident, fellow).



Late Breaking Abstracts

Late breaking submissions will open on August 21 and close on September 30. A placeholder abstract for late-breaking abstracts is not required during the general call for abstracts. Only paradigm shifting basic science discovery, or translational or clinical research of relevance to patients will be considered. Please note that, due to program schedule considerations, most if not all late acceptances will be programmed as posters.